

50. The composition of claim 48 wherein said peptide is selected from the group consisting of CGRP, deamidated CGRP, and reduced CGRP.

51. The composition of claim 48 wherein said peptide is a functional amylin peptide fragment.

52. The composition of claim 48 wherein said peptide is a conservative variant of amylin.

53. The composition of claim 52 wherein said conservative variant of amylin is non-human amylin.

54. The composition of claim 48 wherein said peptide is a CGRP peptide fragment.

55. The composition of claim 48 wherein said peptide is a conservative variant of CGRP.

56. A method for preparing a product for the treatment of diabetes mellitus or hypoglycemia, which method comprises bringing an effective amount of a compound having amylin-like activity into the form of a composition suitable for therapeutic administration.

57. The method of claim 56 wherein said compound is a peptide.

58. The method of claim 57 wherein said peptide is amylin.

59. The method of claim 57 wherein said peptide is selected from the group consisting of deamidated amylin and reduced amylin, alone or in conjunction with amylin.

60. The method of claim 57 wherein said peptide is selected from the group consisting of CGRP, deamidated CGRP, and reduced CGRP.

61. The method of claim 57 wherein said peptide is a functional amylin peptide fragment.

62. The method of claim 57 wherein said peptide is a conservative variant of amylin.

63. The method of claim 57 wherein said conservative variant of amylin is non-human amylin.

64. The method of claim 57 wherein said peptide is a CGRP fragment.

65. The method of claim 57 wherein said peptide is a conservative variant of CGRP.

66. A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a therapeutically effective amount of a peptide having amylin like activity, said composition being lyophilized.

67. A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a therapeutically effective amount of a peptide having amylin-like activity, said composition being disposed in a vehicle suitable for delayed-release administration of said peptide.

68. The composition of claim 67 wherein said composition is formulated with protamine.

69. The composition of claim 67 wherein said composition is formulated with a zinc salt.

70. The composition of claim 68 wherein said composition is formulated with protamine and a zinc salt.

71. The composition of any of claims 69 or 70 wherein said zinc salt is zinc chloride.

72. A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a suspension of a peptide having amylin-like activity, said suspension being formulated with a zinc salt in a